Benzinga··PrnewswirePsilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications
Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials